Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies
Journal of Medicinal Chemistry · 05.11.2026
DOI: 10.1021/acs.jmedchem.6c01475 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 05.11.2026. Verfasst von Leo Faïon und 22 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Métropole européenne de Lille, Canadian Institutes of Health Research, État français.
Abstract (Originalsprache)
Tuberculosis (TB) remains a major global health threat, intensified by rising drug resistance. Tricyclic spirolactam (TriSLa) inhibitors targeting mycobacterial type II NADH dehydrogenases (Ndh/NdhA) represent a promising antibiotic class but previously suffered from poor metabolic stability. Through extensive structure−activity and structure−property optimization, we identified BDM91465, a potent and metabolically stable TriSLa analog. Cryo-EM analysis revealed its binding mode within the menaquinone pocket of Ndh, consistent with observed SAR trends. BDM91465 displayed favorable pharmacokinetics, including good bioavailability and low clearance, resulting in sustained exposure above its MIC. In vivo, BDM91465 significantly reduced Mycobacterium tuberculosis burden in mice, mirroring the phenotype of Ndh-2 genetic inactivation. These findings provide the first demonstration of Ndh-2 inhibition efficacy in a murine model, validating Ndh-2 as a druggable target and supporting further development of TriSLa-based regimen.
Förderung
- Métropole européenne de Lille
- Canadian Institutes of Health Research
- État français
- Canada Research Chairs
- Agence Nationale de la Recherche
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
- Conseil Régional Hauts-de-France
- European Regional Development Fund
Zitieren
APA
Faïon, L., Ho, V. Q. T., Tangara, S., Liang, Y., Boarbi, S., Chatagnon, J., Djaout, K., Adnet, P., Kiass, M., Dam, S., Anoz-Carbonell, E., Fischer, P., Vigier, C., Dumont, J., Eveque, M., Piveteau, C., Leroux, F., Deprez, B., Willand, N., …, & Villemagne, B. (2026). Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01475
Vancouver
Faïon L, Ho VQT, Tangara S, Liang Y, Boarbi S, Chatagnon J, et al. Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01475
BibTeX
@article{Faion2026,
author = {Faïon, Leo and Ho, Vien Q. T. and Tangara, Salia and Liang, Yingke and Boarbi, Samira and Chatagnon, Jonathan and Djaout, Kamel and Adnet, Pierre-Yves and Kiass, Mehdi and Dam, Sushovan and Anoz-Carbonell, Ernesto and Fischer, Pauline and Vigier, Clément and Dumont, Julie and Eveque, Maxime and Piveteau, Catherine and Leroux, Florence and Deprez, Benoit and Willand, Nicolas and Rubinstein, John L. and Mathys, Vanessa and Hartkoorn, Ruben C. and Villemagne, Baptiste},
title = {Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c01475}
}
EUVIMED